Quick Answer
Meihua International Medical Technologies Co., Ltd. reported Total Revenue of $103.35 million for fiscal year 2022.
Meihua International Medical Technologies Co., Ltd. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $103.35M -0.7% |
$104.04M +16.8% |
$89.06M +11.8% |
$79.63M |
| Net Income | $10.84M -6.7% |
$11.63M +86.2% |
$6.24M -70.2% |
$20.95M +10.0% |
$19.05M +23.4% |
$15.43M |
| Diluted EPS | — | $0.49 +81.5% |
$0.27 -74.3% |
$1.05 +10.5% |
$0.95 | — |
| Total Assets | $186.24M +8.3% |
$171.92M +5.1% |
$163.58M +19.5% |
$136.86M +29.1% |
$106.05M | — |
| Cash and Equivalents | — | $16.93M -36.7% |
$26.74M +228.1% |
$8.15M +13.4% |
$7.19M | — |
| Long-Term Debt | — | — | $724.9K | — | — | — |
| Stockholders Equity | $158.98M +8.6% |
$146.33M +5.9% |
$138.12M +28.2% |
$107.77M +27.2% |
$84.74M +42.0% |
$59.66M +34.2% |
| R&D Expense | $3.46M +25.5% |
$2.75M -7.1% |
$2.96M +8.7% |
$2.73M +9.3% |
$2.49M -22.5% |
$3.21M |
| Operating Income | $14.31M -2.5% |
$14.67M +35.9% |
$10.80M -58.9% |
$26.26M +11.9% |
$23.47M +21.0% |
$19.39M |
| Gross Profit | $33.30M +0.3% |
$33.20M -12.9% |
$38.10M -4.3% |
$39.81M +7.1% |
$37.16M +15.4% |
$32.21M |
| Shares Outstanding | 31.90M +33.3% |
23.94M +19.7% |
20.00M +0.0% |
20.00M +0.0% |
20.00M | — |
- Meihua International Medical Technologies Co., Ltd. reported Total Revenue of $103.35 million for fiscal year 2022.
- Meihua International Medical Technologies Co., Ltd. showed a decrease of -0.7% in Total Revenue compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Net Income of $10.84 million for fiscal year 2024.
- Meihua International Medical Technologies Co., Ltd. showed a decrease of -6.7% in Net Income compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Diluted EPS of $0.49 per share for fiscal year 2023.
- Meihua International Medical Technologies Co., Ltd. showed an increase of +81.5% in Diluted EPS compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Total Assets of $186.24 million for fiscal year 2024.
- Meihua International Medical Technologies Co., Ltd. showed an increase of +8.3% in Total Assets compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Cash and Equivalents of $16.93 million for fiscal year 2023.
- Meihua International Medical Technologies Co., Ltd. showed a decrease of -36.7% in Cash and Equivalents compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Long-Term Debt of $724.9 thousand for fiscal year 2022.
- Meihua International Medical Technologies Co., Ltd. reported Stockholders Equity of $158.98 million for fiscal year 2024.
- Meihua International Medical Technologies Co., Ltd. showed an increase of +8.6% in Stockholders Equity compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported R&D Expense of $3.46 million for fiscal year 2024.
- Meihua International Medical Technologies Co., Ltd. showed an increase of +25.5% in R&D Expense compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Operating Income of $14.31 million for fiscal year 2024.
- Meihua International Medical Technologies Co., Ltd. showed a decrease of -2.5% in Operating Income compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Gross Profit of $33.30 million for fiscal year 2024.
- Meihua International Medical Technologies Co., Ltd. showed an increase of +0.3% in Gross Profit compared to the prior fiscal year.
- Meihua International Medical Technologies Co., Ltd. reported Shares Outstanding of 31.90 million shares for fiscal year 2024.
- Meihua International Medical Technologies Co., Ltd. showed an increase of +33.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: